NCT00810953已完成1 期
A Phase I/II Clinical Study Using Pentamidine in Patients With Locally Advanced or Metastatic Pancreatic Cancer Undergoing Standard Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Any severe events, tumor marker CA19-9, and tumor size (CT scan)
研究概览
简要总结
The purpose of this study is to investigate the safety and possible efficacy of the use of pentamidine in the treatment of pancreatic cancer metastasis in subjects receiving standard therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically proven diagnosis of advanced pancreatic adenocarcinoma that is unresectable or metastatic. At least one uni-dimensionally measurable lesion (on spiral CT scan)
- •18 years of age or older
- •ECOG performance status 0, 1 or 2
- •Serum aspartate transaminase (AST) serum alanine transaminase (ALT) £ 2.5 x upper limit of normal (ULN), or AST and ALT £ 5 x ULN if liver function abnormalities are due to underlying malignancy
- •Total serum bilirubin £ 2 x ULN
- •lipase within normal limits (1.5x ULN)
- •Absolute neutrophil count (ANC) ≥ 1500/uL (1.5 x 109/L)
- •Platelets ≥ 100,000/uL
- •Hemoglobin ≥ 9.0 g/dL
- •Serum creatinine £ 1.5 x ULN or calculated creatinine clearance ≥ 50 ml/min
- •CA19-9 level ≥ 37 U/ml
- •Normal ECG
- •Signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrolment
- •Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures
- •Life expectancy, in the opinion of the investigator, > 3 months
排除标准
- •BP < 100 (systolic)
- •History of uncontrolled renal disease, pancreatitis, or diabetes mellitus
- •Peripheral sensory neuropathy (> Grade 1, as per NCI CTCAE version 3.0)
- •Concomitant therapy with other investigational agents or participation in another clinical trial within the previous 3 months.
- •Any of the following conditions: Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥ 2; atrial fibrillation of any grade; QTc interval >450 msec for males or >470 msec for females or uncontrolled intercurrent illness, e.g., unstable angina; severe coronary disease, ventricular arrhythmias, bradycardia <50 bpm
- •Active uncontrolled bacterial infection
- •Concurrent use of drugs that could prolong QT interval
- •Concurrent use of nephrotoxic drugs, including aminoglycosides, ampho B, foscarnet, cidofovir
- •Concurrent use of drugs that may be associated with pancreatitis
- •Concurrent active cancer originating from a primary site other than pancreas or history of cancer < 3 years except for skin superficial bladder, uterus etc
- •History of allergy or hypersensitivity to pentamidine
- •Pregnancy or breastfeeding. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to first dose of study medication.
- •Severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgement of the investigator, excess risk associated with trial participation of study drug administration, or which in the judgement of the investigator, would make the subject inappropriate for entry into this trial.
- •On oral anticoagulants (LMWH is acceptable)
研究组 & 干预措施
single arm
Experimental
Use of pentamidine in locally advanced or metastatic pancreatic cancer
干预措施: Pentamidine (Drug)
结局指标
主要结局
Any severe events, tumor marker CA19-9, and tumor size (CT scan)
时间窗: 6 months
次要结局
- TDP(6 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of Single and Multiple Dose Administration of LP-001 in Healthy SubjectsMyelodysplastic Syndrome (MDS)NCT06294275Longbio Pharma68
已完成
1 期
Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV PatientsChronic HBV InfectionNCT05019040Zhejiang Palo Alto Pharmaceuticals, Inc.36
Unknown
1 期
CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal AdenocarcinomaPancreatic CancerNCT05052567Qilu Pharmaceutical Co., Ltd.50
尚未招募
2 期
Early Application of Memantine and Pioglitazone to Protect Cognitive Function After RadiotherapyRadiation DiseaseCognitive ImpairmentDrug EffectNCT06594172Affiliated Cancer Hospital & Institute of Guangzhou Medical University67
招募中
1 期
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous NephropathyPrimary Membranous NephropathyNCT05668403Shanghai Jiaolian Drug Research and Development Co., Ltd52